CLINICAL EXPERIENCE IN THE TREATMENT OF METASTATICNON–SMALL CELL LUNG CANCER WITH MORE THAN 3 YEARS OF SURVIVAL

Abstract

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer in Bulgaria, as well as worldwide, and is a leading cause of cancer-related mortality in the country. The results of the KEYNOTE-189 clinical trial provide compelling evidence for the effectiveness of adding immunotherapy to standard chemotherapy as the preferred first-line treatment for patients with advanced NSCLC with PD-L1 expression and without EGFR/ALK mutations. The aim of this review is to present our clinical experience with a patient treated with pembrolizumab in the Medical Oncology Clinic at Heart and Brain Hospital Pleven, and to highlight the favourable outcomes from the clinical study, confirming its applicability and evidence-based effectiveness in real-world oncological practice.